Puridify
Nanofiber purification technology for biopharmaceutical manufacturing.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
£190k | Grant | ||
| Total Funding | 000k | ||
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (15 %) | (70 %) | (8854 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (749 %) | (1936 %) | (10215 %) | 88 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (409 %) | (2131 %) | (10802 %) | 100 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 198 % | 452 % | 1312 % | (18 %) | - | - |
Source: Company filings or news article
Related Content
Puridify, founded in 2013 as a spin-out from University College London (UCL), developed a platform purification technology for the biopharmaceutical industry. The company was co-founded by Dr. Oliver Hardwick (CEO) and Dr. Iwan Roberts (COO), who were both alumni of UCL's Biochemical Engineering department. The core technology originated from an engineering doctoral project conceived by UCL’s Professor Dan Bracewell and Professor Bob Stevens of the Science and Technology Facilities Council (STFC), with an initial patent filed in 2012.
The company's main product, FibroSelect, is a nanofiber-based purification platform designed to improve efficiency and reduce costs in the manufacturing of biotherapeutics like enzymes and proteins. Unlike traditional methods that use porous beads, FibroSelect employs a 3D nanofiber material for chromatographic separation, which enables faster mass transfer and greater productivity. This technology was developed to address the growing demand for flexible and small-scale manufacturing solutions in the biologics market. The platform allows for the replacement of large chromatography columns with smaller, ready-to-operate units, which can reduce processing times and validation requirements.
Puridify operated by collaborating with major biopharmaceutical companies to develop and validate its technology for industrial applications. The firm received significant funding from venture capital investors, including Imperial Innovations, SR One, and UCL Business, alongside grants from Innovate UK. In December 2017, Puridify was acquired by GE Healthcare, and its 17 employees joined GE Healthcare's Life Sciences business. The team remained at their base at the Stevenage Bioscience Catalyst, which became a research hub for bioprocessing within GE.
Keywords: bioprocessing, purification technology, nanofiber, biopharmaceutical, chromatography, FibroSelect, biomanufacturing, biologics, downstream processing, protein purification, monoclonal antibodies, gene therapy, viral vectors, process development, single-use technology